Our Story

Noven – 1987 to Today

Noven's history began in 1987 in Miami, Florida, with the mission to develop differentiated prescription transdermal drug delivery systems (patches) to benefit patients across a range of therapeutic conditions. Today, Noven is the US platform for Hisamitsu, the world's largest patch manufacturer, with fully integrated R&D, clinical, manufacturing, and sales functions offering prescription products in the areas of women's health and mental health.

History

2020
March

Launch of SECUADO®

Secuado Boxes
2019
October

SECUADO® (asenapine) transdermal system FDA approval

2016
June

Brisdelle® (paroxetine) and Pexeva® (paroxetine) acquired by Sebela Pharmaceuticals

2015
February

New Minivelle® (estradiol transdermal system) 0.025 mg/day Dose Now Available by Prescription in U.S. Pharmacies

2013
November

Launch of Brisdelle®

June

Brisdelle® approved by the FDA

January

Noven Women's Health team launches Minivelle®

2012
December

Noven acquires Minivelle®, establishes Women's Health sales team

October

Minivelle®, world's smallest estrogen patch, approved by FDA

2011
February

Noven's Northeast operations consolidated in Empire State Building co-headquarters

2010
February

Noven reacquires Daytrana® (methylphenidate transdermal system) from Shire

February

Hisamitsu Carlsbad facility integrated with Noven operations

2009
February

Noven acquired by Hisamitsu Pharmaceuticals; public company status concludes

2007
February

Noven acquires JDS Pharmaceuticals, expanding its portfolio and sales capabilities

2006
February

Shire and Noven launch Daytrana®

2003
February

Shire licenses Noven's Daytrana® patch for ADHD

1999
February

Launch of Vivelle-Dot® (estradiol transdermal system), the world's smallest estrogen patch at the time

1998
February

Launch of CombiPatch® (estradiol/norethindrone acetate transdermal system), the first combination (two-drug) patch

February

Formation of Novogyne joint venture in Women's Health

1996
February

Launch of Vivelle® (estradiol transdermal system), the first adhesive matrix estrogen patch

1988
February

Noven becomes a public company

1987
February

Noven founded by Steven Sablotsky

Fast Facts

Core Business:
Specialty pharmaceutical company engaged in the research, development, manufacture, marketing and sale of prescription pharmaceutical products.

Year of Incorporation:
1987

Employees:
Over 300

Chairman &
Chief Executive Officer:
Dr. Naruhito Higo

Media, General Business
& Other Inquiries:
CorporateAffairs@noven.com

Partnering and Other Business Development Opportunities
Tel: 551-233-2700
BusDev@noven.com

Employment Inquiries:
Marilyn Reynaldo
Associate Director –
Talent Acquisition
mreynaldo@noven.com

Community Support:
Corporate Social Responsibility

Affiliated Companies:
Noven is a wholly-owned subsidiary of Hisamitsu Pharmaceutical Co., Inc. – bringing the benefits of patch therapy to patients around the world.

Noven's commercialized products are marketed and sold through Noven Therapeutics, LLC.

Grove Pharmaceuticals is the generic division of Noven Therapeutics, LLC.